Article Details
Retrieved on: 2018-05-02 17:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Thirty-five years after that first encounter in the chemical engineering building at MIT — Building 66 — Keith Dionne and Frank Gentile, are leading a new Cambridge biotech, Casma Therapeutics Inc. It was formally launched Thursday by <b>Third Rock Ventures</b> with more than $58 million in venture capital.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here